OSU6162 in Bipolar Depression (OBID)

Bipolar Depression Clinical Trial

— OBID  

Official title:

OSU6162 in Bipolar Depression: An Open-label, Flexible Dose Study (OBID)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05296356
• Other study ID #: EudraCT number: 2020-001980-95
• Secondary ID: 2020-001980-95
• Status: Recruiting
• Phase: Phase 2
• Start date: October 25, 2021
• Est. completion date: May 31, 2027

Study information

• Verified date: October 2023
• Source: Göteborg University
• Contact: Elias Eriksson, Professor
• Phone: + 46 709 555055
• Email: elias.eriksson[@]neuro.gu.se
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

An explorative, open label, single armed, flexible dose, single center, phase IIa study of 8 weeks, initiated in inpatients with bipolar depression. The study will consist of 9 visits and 1 safety visit.

Inpatients with a primary diagnosis of bipolar disorder (type 1 or 2) currently in an acute depressive phase (i.e. bipolar depression) and being on stable medication with at least one mood stabilizer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 22
• Est. completion date: May 31, 2027
• Est. primary completion date: May 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Signed informed consent

2. Voluntary admission to the psychiatric ward prior or directly after the screening point

3. Age: 18-65 on the day of screening

4. Meeting DSM-5 criteria for a depressive episode in Bipolar Disorder type I or type II, as confirmed by the Mini International Neuropsychiatric Interview (MINI)

5. Displaying a sum score of =10 on the Bech 6-item subscale of the Hamilton Depression rating Scale.

6. Treatment with a stable dose of a mood stabilizer since at least 4 weeks before screening: lithium s-conc> 0,45 mmol/L; >lamotrigine dose 100 mg/d; >valproate dose > 900 mg/d, >carbamazepine concentration >20 mmol/L

7. In female patients of childbearing potential: negative result of a pregnancy test and a method of contraception with a failure rate of less than 1 %. Women of childbearing potential must, for inclusion, use a highly efficient method of contraception, i.e. a method with a failure rate of less than 1% (e.g. sterilization, hormone implants, hormone injections, some intrauterine devices, or vasectomy in partner).

8. Male patients must agree to use condoms during the study and for 2 weeks after the end of the study/last dose of IMP, unless their partner is using a highly efficient method of contraception, as described above.

Exclusion Criteria:

1. Ongoing compulsory care.

2. Subject is considered by the investigator to be at imminent risk of suicide or injury to self, others, or property.

3. Previously diagnosed or meeting MINI criteria at interview for obsessive-compulsive disorder or post-traumatic stress disorder.

4. A previous diagnosis of a personality disorder, autism, ADHD, or intellectual disability.

5. A history of substance/alcohol abuse within 2 years prior to screening.

6. Any other previously diagnosed or suspected CNS disorder that according to the investigator renders the patient unsuitable for participation in the trial (such as dementia, brain injury, and epilepsy).

7. Young Mania Rating Scale (YMRS) total score of >12 at screening or at any time during the trial.

8. Any somatic illness that according to the investigator renders the patient unsuitable for participation in the trial.

9. Any signs or symptoms of somatic illness resulting from assessment of vital signs, physical examination, clinical laboratory tests or 12- lead ECG that according to the investigator renders the patient unsuitable for participation for safety reasons, including a QTc-time on ECG exceeding 450 ms in men and 460 ms in women.

10. Any factor that according to the investigator renders it unlikely that the patient will comply with the instructions regarding treatment, visits etc.

11. Any change in medication (including dosage) of an antidepressant drug or a mood stabiliser within 4 weeks prior to screening or at any time during the trial.

12. Ongoing treatment with potent cytochrome P450 enzyme inhibitors (e.g., bupropion, fluvoxamin, ketoconazol, itraconazole, telitromycin, clarithromycin, protease inhibitors, quinidine, and terbinafine).

13. Ongoing treatment with drugs displaying a narrow therapeutic window - with the exception of lithium - where either reduced or increased serum levels are potentially harmful (including but not limited to warfarin, other anticoagulants, digoxin. other antiarrythmics, anticonvulsants when prescribed for treatment of epilepsy but not when prescribed for bipolar disorder, cyclosporine, and immunosuppressants).

14. Ongoing treatment with drugs with dopaminergic synapses as primary site of action (e.g., antipsychotics, bupropion, central stimulants, and drugs for Parkinson's disease).

15. No observed beneficial effect of treatment and a symptom severity that by the investigator's assessment would render continued participation unethical.

16. Previous intake of OSU6162.

17. Current participation in another clinical trial.

18. Nursing women.

Related Conditions & MeSH terms

• Bipolar Depression
• Bipolar Disorder
• Depression
• Depressive Disorder

Intervention

Drug:
• OSU6162
OSU6162

Locations

Country	Name	City	State
Sweden	Sahlgrenska university hospital/Östra	Gothenburg

Sponsors (2)

Lead Sponsor	Collaborator
Göteborg University	Arvid Carlsson Research AB

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) at endpoint [Day 60].		Endpoint at 60 days treatment